The Advisory Board acts as a resource and wise counsel for the consortium executive steering committee. The Board provides oversight, monitors progress, and ensures compliance of the consortium activities, commensurate with the consortium mission, vision, and values.
Advisory Board members are basic/translational scientists or clinicians. They are unbiased, and experienced either as scientific/medical advisors at the national level, or in leadership positions at national scientific organisations. They serve a 3-year term on the Board. Their recommendations, albeit non-binding, are considered seriously by the executive steering committee. Board members have fiduciary duties to the consortium and are required to disclose any conflict of interest.
Justin D. Lathia, PhD
Professor, Lerner Research Institute
Cleveland Clinic
Cleveland, OH, USA
Dorothy Keefe, PSM, MBBS, MSc, MD, FRCP
CEO, Cancer Australia
Honorary Clinical Professor, School of Medicine
Faculty of Health Sciences, University of Adelaide
Sydney, NSW, Australia
Jame Abraham, MD, FACP
Professor and Chairman, Department of Hematology and Medical Oncology
Deputy Director, Case Comprehensive Cancer Center
Acting Chair, Cleveland Clinic Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH, USA
Manmeet S. Ahluwalia, MD, MBA
Chief of Medical Oncology
Chief Scientific Officer & Deputy Director
Miami Cancer Institute
Miami, FL, USA
Hellmut Augustin, DVM, PhD
Professor, Vascular Biology
Medical Faculty Mannheim of Heidelberg University
Head of the Division for Vascular Oncology and Metastasis Research
German Cancer Research Center
Heidelberg, Germany
Sharmila A. Bapat, PhD
Scientist-F, National Centre for Cell Science
Pune University Campus
Pune, Maharashtra, India
Luisa Iruela-Arispe, PhD
Chair, Department of Cell and Developmental Biology
Stephen Walter Ranson Professor of Cell Biology
Feinberg School of Medicine
Northwestern University
Chicago, IL, USA